

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information if it does not have a valid OMB control number.				<b>Complete if Known</b>	
Substitute for form 1449A/PTO				Application Number	10/644,579-Conf. #5200
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Filing Date	August 20, 2003
(Use as many sheets as necessary)				First Named Inventor	Connie Sanchez
				Art Unit	1617
				Examiner Name	Y. S. Chong
Sheet	1	of	4	Attorney Docket Number	05432/100M919-US1

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference concides, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not concordant. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that patent was filed after June 30, 2003 or is available in the IFW. \* Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at [www.uspto.gov/mpep](http://www.uspto.gov/mpep) 301.04. Error: Office that issued the cited document is not indicated by the word "OFFICE OF THE PATENT EXAMINER IN CHARGE," the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/644,579-Conf. #5200
		Filing Date	August 20, 2003
		First Named Inventor	Connie Sanchez
		Art Unit	1617
		Examiner Name	Y. S. Chong
Sheet	2	of	4
		Attorney Docket Number	05432/100M919-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>1</sup>
	10	Notice of Opposition to EP Patent No. 1 200 081 filed by EGIS GYOGYSZERGYAR NYRT. (June 14, 2007)	
	11	Notice of Opposition to EP Patent No. 1 200 081 filed by GENERICS (UK) LIMITED. (June 19, 2007)	
	12	Notice of Opposition to EP Patent No. 1 200 081 filed by HEXAL PHARMA AG. (June 20, 2007)	
	13	Notice of Opposition to EP Patent No. 1 200 081 filed by Pliva Hrvatska d.i. (June 21, 2007)	
	14	Notice of Opposition to EP Patent No. 1 200 081 filed by Richter Gedeon R.T. (June 20, 2007)	
	15	Notice of Opposition to EP Patent No. 1 200 081 filed by TEVA PHARMACEUTICAL INDUSTRIES LTD. (June 20, 2007)	
	16	NZ Examination Report for NZ App. No. 569150 (June 24, 2008)	
	17	E.J. ARIENS "Chirality in Bioactive Agents and its Pitfalls." TIPS, May 1986:200-205.	
	18	P. BAUMANN, "Care of depression in the elderly: comparative pharmacokinetics of SSRIs," International Clinical Psychopharmacology 1998, Vol. 13 (suppl 5) S35-S43.	
	19	R.J. BOERNER, et al. "The Importance of new Antidepressants in the Treatment of Anxiety/Depressive Disorders. Pharmacopsychiat. 32 (1999): 119-126.	
	20	BONDOLFI, "Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation," Psychopharmacology (1996) 128:421-425.	
	21	O. BRAWMAN-MINTZER, "Psychiatric Comorbidity in Patients with Generalized Anxiety Disorder," Am J Psychiatry 150:8, August 1993, pp 1216 - 1218.	
	22	K. M. CONNOR, "Generalized Anxiety Disorder: Neurobiological and Pharmacotherapeutic Perspectives," Biol Psychiatry 1993; 44:1286-1294.	
	23	CUTLER, "A Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Ipsapirone Versus Lorazepam in Patients With Generalized Anxiety Disorder: A Prospective Multicenter Trial," Journal of Clinical Psychopharmacology, Vol. 13, No. 6, (1993), pp. 429-437.	
	24	Larry CULPEPPER, M.D., "Escitalopram: A New SSRI for the Treatment of Depression in Primary Care," Primary Care Companion J. Clin Psychiatry 2002;4(6) pp. 209 - 214.	
	25	N. P. EMMANUEL, "Sertraline in Generalized Anxiety Disorder, A Case Series," Psychopharmacology Bulletin p. 518	
	26	Fachinformation, CipraleX® (Escitalopram) (10 mg/20 mg) (Product Description)	
	27	Fachinformation, Cipramil® (Citalopram) (20 mg/40 mg) (Product Description)	
	28	FDA's Policy Statement for the Development of New Stereoisomeric Drugs, FDA website. <http://www.fda.gov/oc/drug/guidance/stereo.htm>, printed September 5, 2007	
	29	"Forest Aerobid Market Share is Stable at 10%-10.5%, Firm Reports. (September 28, 1998) Vol. 60, No. 39, p. 19.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO  <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(Use as many sheets as necessary)</i></p>		<b>Complete if Known</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Application Number</td> <td>10/644,579-Conf. #5200</td> </tr> <tr> <td>Filing Date</td> <td>August 20, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Connie Sanchez</td> </tr> <tr> <td>Art Unit</td> <td>1617</td> </tr> <tr> <td>Examiner Name</td> <td>Y. S. Chong</td> </tr> <tr> <td>Attorney Docket Number</td> <td>05432/100M919-US1</td> </tr> </table>		Application Number	10/644,579-Conf. #5200	Filing Date	August 20, 2003	First Named Inventor	Connie Sanchez	Art Unit	1617	Examiner Name	Y. S. Chong	Attorney Docket Number	05432/100M919-US1
Application Number	10/644,579-Conf. #5200														
Filing Date	August 20, 2003														
First Named Inventor	Connie Sanchez														
Art Unit	1617														
Examiner Name	Y. S. Chong														
Attorney Docket Number	05432/100M919-US1														
Sheet	3	of	4												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	30	Shinji HASHIMOTO, Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats, <i>European Journal of Pharmacology</i> 378 (1999) 23-30.	
	31	Shinji HASHIMOTO, Effects of the Co-administration of 5-HT1a Receptor Antagonists with an SSRI in Conditioned Fear Stress-Induced Freezing Behavior, <i>Pharmacology Biochemistry and Behavior</i> , Vol. 58, No. 2, pp. 471-475, 1997.	
	32	Shinji HASHIMOTO, Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats, <i>Psychopharmacology</i> (1996) 123: pp. 182-186.	
	33	S. HOGG, The antidepressant effects of citalopram are mediated by the S-(+) and not the R-(-) enantiomer, <i>European Neuropsychopharmacology</i> , Vol. 9, Supplement 5, 1999, p. S213.	
	34	A.J. HUTT, Drug Chirality and its Clinical Significance," <i>Drugs</i> 1996: 52, Suppl. 5, pp. 1-12.	
	35	Takeshi INOUE, Serotonergic Activation Reduces Defensive Freezing in the Conditioned Fear Paradigm, <i>Pharmacology Biochemistry and Behavior</i> , Vol. 53, No. 4, pp. 825-831, 1996.	
	36	M. KOSEL, Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography, <i>Journal of Chromatography B</i> , 719 (1998) pp. 234-238.	
	37	Y.W. Francis LAM, Pharm. D. Stereoselectivity: An Issue of Significant Importance in Clinical Pharmacology, <i>Pharmacotherapy</i> , Vol. 8, No. 3, 1988, pp. 147-157.	
	38	G. LAUX, Psychoopharmacological Treatment of Anxiety Disorders, <i>Therapeutische Umschau</i> , Vol. 54, No. 10, 1997, pp. 595-599.	
	39	LEPOLA et al., Citalopram in Anxiety Disorder of Childhood and Adolescence, <i>Eur. Child. Adol. Psych.</i> , 1994 3(4):277-279.	
	40	LEPOLA et al., The effect of citalopram in panic disorder and agoraphobia, <i>Nord. J. Psych.</i> , 1994, 48:13-17.	
	41	J.P. LHUILLIER, Maprotiline Drops: Pilot Study in Anxiety Adaptive Disorders, <i>Psychiatry Today: Accomplishments and Promises</i> , International Congress Series, Elsevier Science Publishers B.V., 1989.	
	42	Lundbeck Annual Report 1999 (C. G. GOTTFRIES, "Citalopram benefits society," p. 26)	
	43	Lundbeck Annual Report 1998 (Development Projects, p. 68)	
	44	R. B. LYDIARD, Recent Developments in the Psychopharmacology of Anxiety Disorders, <i>Journal of Consulting and Clinical Psychology</i> 1996 Vol. 64, No. 4, pp. 660-668.	
	45	W. MAIER, The Epidemiology of comorbidity between depression, anxiety disorders and somatic diseases, <i>International Clinical Psychopharmacology</i> , May 1999: 14 Suppl 2: S1-6.	
	46	Merck Manual of Diagnostics, Home Edition, 1997, pp. 438-447	
	47	S. NOBLE, Citalopram: A Review of its Pharmacology, Clinical Efficacy, and Tolerability in the Treatment of Depression, <i>CNS Drugs</i> 1997 Nov: 8 (5): 410-431	
	48	G. PARKER, Early onset depression: the relevance of anxiety, <i>Soc Psychiatry Psychiatr Epidemiol</i> (1997) 32: 30-37.	
	49	<i>Psychopharmaka Rote Liste</i> 1998, Cipramil® (Citalopram HBr) p. 127.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete If Known</b> Application Number 10/644,579-Conf. #5200 Filing Date August 20, 2003 First Named Inventor Connie Sanchez Art Unit 1617 Examiner Name Y. S. Chong Attorney Docket Number 05432/100M919-US1	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)					
Sheet	4	of	4		

[illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.